U.S. BioDefense To Partner With MD Andersen

U.S. BioDefense (OTCBB:UBDE) announced that it has entered into a definitive agreement with the University of Texas MD Anderson Cancer Center. The company has the priority option to review and license the patent pending technology entitled ``Use of Non-marrow Stem Cell for Cardiac Regeneration''. Bone Marrow and Stem Cell Transplants can be Life-Saving for People with Blood Cancers, Solid Tumors and Some Non-Cancerous Blood Disorders. CEO David Chin stated that, ``We are very excited to announce to shareholders that the company has entered into an evaluation agreement for the cardiac regeneration of stem cell technology. Currently, the use of these stem cells for myocardial regeneration may prove to be superior to other stem cell sources by circumventing the pain and anesthesia complications associated with bone marrow aspiration procedures, by doing so would also reduce the number of deaths associated with bone marrow transplants.'' Array BioPharma Inc. (Nasdaq: ARRY) announced that a scientific poster will be presented at the American Society of Clinical Oncology Annual Meeting in Orlando, Florida....

Posted on May 13, 2005 04:54 PM